Published Date:2021-02-15 Original Link:https://www.onenessbio.com/en/news_detail27_4.htm No 1 Date of announcement   2021/02/15 Time of announcement  08:42:18 Subject Oneness submits an IND to US FDA on a phase II clinical trial on severe asthma of FB704A, a mAb developed from its own platform.      To which item it meets paragraph 10 Date of events  2021/02/13 Statement 1.Product:FB704A...Read More